GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Reimbursement in Germany came up on NVS’ CC this morning with respect to Lucentis. Here’s what was said in reply to a question:

“In Germany and certain other countries, until full reimbursement is granted they’re managing this process through the hospitals and they just want to make sure the patient has been appropriately diagnosed and that specialists are administering the drug correctly.”

In other words, it’s possible for a clinician to request off-label or pre-approval reimbursement for an individual patient, but there is a considerable amount of red tape involved.